X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    〈sup〉68〈/sup〉Ga-FAPI-04 PET/CT for Molecular Assessment of Fibroblast Activation and Risk Stratification in Systemic Sclerosis-Related Interstitial Lung Disease
    Elsevier BV ; 2020
    In:  SSRN Electronic Journal
    Details
    In: SSRN Electronic Journal, Elsevier BV
    Type of Medium: Online Resource
    ISSN: 1556-5068
    URL: Article
    DOI: 10.2139/ssrn.3622367
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 2
    Online Resource
    Online Resource
    68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study
    Elsevier BV ; 2021
    In:  The Lancet Rheumatology Vol. 3, No. 3 ( 2021-03), p. e185-e194
    Details
    In: The Lancet Rheumatology, Elsevier BV, Vol. 3, No. 3 ( 2021-03), p. e185-e194
    Type of Medium: Online Resource
    ISSN: 2665-9913
    URL: Article
    DOI: 10.1016/S2665-9913(20)30421-5
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 3
    Online Resource
    Online Resource
    99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer
    Ovid Technologies (Wolters Kluwer Health) ; 2020
    In:  Clinical Nuclear Medicine Vol. 45, No. 8 ( 2020-8), p. e349-e357
    Details
    In: Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 45, No. 8 ( 2020-8), p. e349-e357
    Abstract: This study aims to investigate the value of 99m Tc-MIP-1404 SPECT/CT for assessment of whole-body tumor burden and treatment response in patients with biochemical recurrence of prostate cancer who undergo androgen deprivation therapy (ADT) or external beam radiation therapy (EBRT). Methods A total of 125 patients with biochemical recurrence of prostate cancer underwent 99m Tc-MIP-1404 SPECT/CT. All 364 prostate-specific membrane antigen (PSMA)–positive lesions in the field of view were assessed quantitatively to calculate PSMA-derived metabolic tumor parameters, including whole-body PSMA tumor volume and whole-body total lesion PSMA. These metrics were correlated with serum prostate-specific antigen (PSA) levels and Gleason scores. In a subset of 50 patients who underwent 99m Tc-MIP-1404 SPECT/CT before the initiation of ADT or EBRT, TL-PSMA and SUV max were compared with radiographic response assessment by CT based on RECIST 1.1 and to biochemical response (BR) determined by changes in serum PSA levels. Results Serum PSA levels correlated with SUV max , whole-body PSMA tumor volume, and whole-body total lesion PSMA in patients with 1 and in those with more than 1 PSMA-positive lesion ( P 〈 0.05). The correlations were significant for both well-differentiated (Gleason score ≤7) and poorly differentiated tumors (Gleason score ≥8) ( P 〈 0.05). The agreement between TL-PSMA derived from SPECT and BR in patients who underwent 99m Tc-MIP-1404 SPECT/CT before and after initiation of ADT was 80% (95% confidence interval [CI], 0.43–0.91; Cohen κ = 0.68; P 〈 0.05); in these patients, the agreement between TL-PSMA and CT was 60% (95% CI, 0.20–0.72; Cohen κ = 0.46; P 〈 0.05) and the agreement between BR and CT was 52% (0.07–0.61; Cohen κ = 0.34; P 〈 0.05). Comparable results were found for patients who underwent SPECT/CT before and after initiation of EBRT, with the strongest agreement between TL-PSMA and BR (80%; 95% CI, 0.38–0.93; Cohen κ = 0.66; P 〈 0.05) compared with the agreement between TL-PSMA and CT (60%; 95% CI, 0.13–0.69; Cohen κ = 0.69; P 〈 0.05) and between BR and CT (48%; 95% CI, 0–0.54; Cohen κ = 0.26; P = 0.11). Discordant findings between SPECT and CT were most likely due to limitations in the assessment of small lymph node metastases and bone involvement, which were detectable on SPECT but not on CT. Conclusions The results of our study show that 99m Tc-MIP-1404 SPECT/CT is a promising method for the evaluation of treatment response in patients with biochemical recurrence of prostate cancer who undergo either ADT or EBRT. TL-PSMA for assessment of treatment response has the strongest correlation with serum PSA levels, superior to SUV max -based evaluation and response assessment based on CT data and RECIST 1.1.
    Type of Medium: Online Resource
    ISSN: 1536-0229 , 0363-9762
    URL: Article
    DOI: 10.1097/RLU.0000000000003102
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2020
    detail.hit.zdb_id: 2045053-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 4
    Online Resource
    Online Resource
    Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer
    Georg Thieme Verlag KG ; 2020
    In:  Nuklearmedizin Vol. 59, No. 05 ( 2020-09), p. 365-374
    Details
    In: Nuklearmedizin, Georg Thieme Verlag KG, Vol. 59, No. 05 ( 2020-09), p. 365-374
    Abstract: Objective Patients with advanced prostate cancer are suitable candidates for [177Lu] PSMA-617 therapy. Integrated SPECT/CT systems have the potential to improve the accuracy of patient-specific tumor dosimetry. We present a novel patient-specific Monte Carlo based voxel-wise dosimetry approach to determine organ and total tumor doses (TTD). Methods 13 patients with histologically confirmed metastasized castration-resistant prostate cancer were treated with a total of 18 cycles of [177Lu]PSMA-617 therapy. In each patient, dosimetry was performed after the first cycle of [177Lu] PSMA-617 therapy. Regions of interest were defined manually on the SPECT/CT images for the kidneys, spleen and all 295 PSMA-positive tumor lesions in the field of view. The absorbed dose to normal organs and to all tumor lesions were calculated by a three dimensional dosimetry method based on Monte Carlo Simulations. Results The average dose values yielded the following results: 2.59 ± 0.63 Gy (1.67–3.92 Gy) for the kidneys, 0.79 ± 0.46 Gy (0.31–1.90 Gy) for the spleen and 11.00 ± 11.97 Gy (1.28–49.10 Gy) for all tracer-positive tumor lesions. A trend towards higher TTD was observed in patients with Gleason Scores 〉  8 compared to Gleason Scores ≤ 8 and in lymph node metastases compared to bone metastases. A significant correlation was determined between the serum-PSA level before RLT and the TTD (r = –0.57, p  〈  0.05), as well as between the TTD with the percentage change of serum-PSA levels before and after therapy was observed (r = –0.57, p  〈  0.05). Patients with higher total tumor volumes of PSMA-positive lesions demonstrated significantly lower kidney average dose values (r = –0.58, p  〈  0.05). Conclusion The presented novel Monte Carlo based voxel-wise dosimetry calculates a patient specific whole-body dose distribution, thus taking into account individual anatomies and tissue compositions showing promising results for the estimation of radiation doses of normal organs and PSMA-positive tumor lesions.
    Type of Medium: Online Resource
    ISSN: 0029-5566 , 2567-6407
    URL: Article
    DOI: 10.1055/a-1204-9932
    Language: English
    Publisher: Georg Thieme Verlag KG
    Publication Date: 2020
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 5
    Online Resource
    Online Resource
    Ultrasound characteristics of follicular and parafollicular thyroid neoplasms: diagnostic performance of artificial neural network
    Springer Science and Business Media LLC ; 2023
    In:  Thyroid Research Vol. 16, No. 1 ( 2023-08-28)
    Details
    In: Thyroid Research, Springer Science and Business Media LLC, Vol. 16, No. 1 ( 2023-08-28)
    Abstract: Ultrasound is the first-line imaging modality for detection and classification of thyroid nodules. Certain features observable by ultrasound have recently been equated with potential malignancy. This retrospective cohort study was conducted to test the hypothesis that radiomics of the four categorical divisions (medullary [MTC], papillary [PTC] , or follicular [FTC] carcinoma and follicular thyroid adenoma [FTA] ) demonstrate distinctive sonographic characteristics. Using an artificial neural network model for proof of concept, these sonographic features served as input. Methods A total of 148 patients were enrolled for study, all with confirmed thyroid pathology in one of the four named categories. Preoperative ultrasound profiles were obtained via standardized protocols. The neural network consisted of seven input neurons; three hidden layers with 50, 250, and 100 neurons, respectively; and one output layer. Results Radiomics of contour, structure, and calcifications differed significantly according to nodule type ( p  = 0.025, p  = 0.032, and p  = 0.0002, respectively). Levels of accuracy shown by artificial neural network analysis in discriminating among categories ranged from 0.59 to 0.98 (95% confidence interval [CI]: 0.57–0.99), with positive and negative predictive ranges of 0.41–0.99 and 0.78–0.97, respectively. Conclusions Our data indicate that some MTCs, PTCs, FTCs, and FTAs have distinctive sonographic characteristics. However, a significant overlap of these characteristics may impede an explicit classification. Further prospective investigations involving larger patient and nodule numbers and multicenter access should be pursued to determine if neural networks of this sort are beneficial, helping to classify neoplasms of the thyroid gland.
    Type of Medium: Online Resource
    ISSN: 1756-6614
    URL: Article
    DOI: 10.1186/s13044-023-00168-2
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 2454440-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 6
    Online Resource
    Online Resource
    Growth rates of malignant and benign thyroid nodules in an ultrasound follow-up study: a retrospective cohort study
    Springer Science and Business Media LLC ; 2019
    In:  BMC Cancer Vol. 19, No. 1 ( 2019-12)
    Details
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 19, No. 1 ( 2019-12)
    Abstract: Thyroid nodules are frequently detected by cervical ultrasound examinations. In follow-up studies, malignant as well as benign nodules may exhibit an increase in size. The objective of our investigation was to test whether histologically determined malignant and benign thyroid nodules show differences in growth rates above a defined significance level. Methods A retrospective ultrasound cohort follow-up study from 4 to 132 months included 26 patients with differentiated carcinomas and 26 patients with adenomas of the thyroid gland. Significance levels were determined by intra- and interobserver variations of volumetric measurements in 25 individuals. Results Intra- and interobserver volumetric measurements were highly correlated ( r  = 0.99 and r  = 0.98, respectively), with variations of 28 and 40%, respectively. The growth rates of malignant and benign nodules did not show differences with respect to two sonographic measurements (d = − 0.04, 95%CI(P): 0.41–0.85, P  = 0.83). Using shorter increments and multiple measurements, growth rates of malignant nodules revealed significantly higher values (d = 0.16, 95%CI(P): 0.02–0.04, P  = 0.039). Conclusions The growth rates of benign and malignant thyroid nodules do not appear to differ using two sonographic volumetric measurements. However, due to temporal changes in cellular proliferation and arrest, malignant nodules may exhibit higher growth rates with multiple assessments and shorter increments.
    Type of Medium: Online Resource
    ISSN: 1471-2407
    URL: Article
    DOI: 10.1186/s12885-019-6348-z
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 2041352-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 7
    Online Resource
    Online Resource
    Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. 11 ( 2020-11), p. 1485-1491
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. 11 ( 2020-11), p. 1485-1491
    Abstract: To date, there is no valuable tool to assess fibrotic disease activity in humans in vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease activity in fibroinflammatory diseases such as IgG 4 -related disease. Methods In this cross-sectional clinical study, 27 patients with inflammatory, fibrotic and overlapping manifestations of IgG 4 -related disease underwent positron emission tomography (PET) scanning with tracers specific for fibroblast activation protein (FAP; 68 Ga-FAP inhibitor (FAPI)-04), 18 F-fluorodeoxyglucose (FDG), MRI and histopathological assessment. In a longitudinal approach, 18 F-FDG and 68 Ga-FAPI-04 PET/CT data were evaluated before and after immunosuppressive treatment and correlated to clinical and MRI data. Results Using combination of 68 Ga-FAPI-04 and 18 F-FDG-PET, we demonstrate that non-invasive functional tracking of IgG 4 -related disease evolution from inflammatory towards a fibrotic outcome becomes feasible. 18 F-FDG-PET positive lesions showed dense lymphoplasmacytic infiltration of IgG 4 + cells in histology, while 68 Ga-FAPI-04 PET positive lesions showed abundant activated fibroblasts expressing FAP according to results from RNA-sequencing of activated fibroblasts. The responsiveness of fibrotic lesions to anti-inflammatory treatment was far less pronounced than that of inflammatory lesions. Conclusion FAP-specific PET/CT permits the discrimination between inflammatory and fibrotic activity in IgG 4 -related disease. This finding may profoundly change the management of certain forms of immune-mediated disease, such as IgG 4 -related disease, as subtypes dominated by fibrosis may require different approaches to control disease progression, for example, specific antifibrotic agents rather than broad spectrum anti-inflammatory treatments such as glucocorticoids.
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-217408
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 8
    Online Resource
    Online Resource
    Multispectral single chip reconstruction using DNNs with application to open neurosurgery
    Walter de Gruyter GmbH ; 2021
    In:  Current Directions in Biomedical Engineering Vol. 7, No. 2 ( 2021-10-01), p. 37-40
    Details
    In: Current Directions in Biomedical Engineering, Walter de Gruyter GmbH, Vol. 7, No. 2 ( 2021-10-01), p. 37-40
    Abstract: Multispectral imaging devices incorporating up to 256 different spectral channels have recently become available for various healthcare applications, as e.g. laparoscopy, gastroscopy, dermatology or perfusion imaging for wound analysis. Currently, the use of such devices is limited due to very high investment costs and slow capture times. To compensate these shortcomings, single sensors with spectral masking on the pixel level have been proposed. Hence, adequate spectral reconstruction methods are needed. Within this work, two deep convolutional neural networks (DCNN) architectures for spectral image reconstruction from single sensors are compared with each other. Training of the networks is based on a huge collection of different MSI imagestacks, which have been subsampled, simulating 16-channel single sensors with spectral masking. We define a training, validation and test set (‘HITgoC’) resulting in 351 training (631.128 sub-images), 99 validation (163.272 sub-images) and 51 test images. For the application in the field of neurosurgery an additional testing set of 36 image stacks from the Nimbus data collection is used, depicting MSI brain data during open surgery. Two DCNN architectures were compared to bilinear interpolation (BI) and an intensity difference (ID) algorithm. The DCNNs (ResNet-Shinoda) were trained on HITgoC and consist of a preprocessing step using BI or ID and a refinement part using a ResNet structure. Similarity measures used were PSNR, SSIM and MSE between predicted and reference images. We calculated the similarity measures for HitgoC and Nimbus data and determined differences of the mean similarity measure values achieved with the ResNet-ID and baseline algorithms such as BI algorithm and ResNet-Shinoda. The proposed method achieved better results against BI in SSIM (.0644 vs. .0252), PSNR (15.3 dB vs. 9.1 dB) and 1-MSE*100 (.0855 vs. .0273) and compared to ResNet-Shinoda in SSIM (.0103 vs. .0074), PSNR (3.8 dB vs. 3.6 dB) and 1-MSE*100 (.0075 vs. .0047) for HITgoC/Nimbus. In this study, significantly better results for spectral reconstruction in MSI images of open neurosurgery was achieved using a combination of ID-interpolation and ResNet structure compared to standard methods.
    Type of Medium: Online Resource
    ISSN: 2364-5504
    URL: Article
    DOI: 10.1515/cdbme-2021-2010
    Language: English
    Publisher: Walter de Gruyter GmbH
    Publication Date: 2021
    detail.hit.zdb_id: 2835398-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 9
    Online Resource
    Online Resource
    SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  Clinical Nuclear Medicine Vol. 43, No. 4 ( 2018-4), p. 225-231
    Details
    In: Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 43, No. 4 ( 2018-4), p. 225-231
    Abstract: 99m Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) is a novel ligand binding to prostate-specific membrane antigen suitable for SPECT. There are, as yet, no data concerning its use in whole-body primary staging and its interobserver variability in patients with prostate cancer (PC) prior to therapy. Methods A search of our clinical database from April 2013 to May 2017 yielded 93 patients with histologically confirmed cancer in whom 99m Tc-MIP-1404 SPECT/CT had been performed for primary whole-body staging before therapy. Whole-body planar and SPECT/CT images of the lower abdomen and thorax had been obtained 3 to 4 hours postinjection of 706 ± 72 MBq 99m Tc-MIP-1404. Images were visually analyzed for extent and location of abnormal uptake by 2 experienced nuclear physicians. Interobserver agreement for detection of primary tumor and metastatic lesions was assessed. In addition, SUVs of prostate-specific membrane antigen–positive regions of the prostate were determined in all patients, and from these, a variable reflecting total tumor load in the prostate gland was calculated (TU prostate ). Follow-up reports of subsequent therapeutic interventions were available in 52 (56%) of all patients with a median follow-up of 18 months. Results In 90 (97%) of 93 patients, prostate uptake above background was detected as correlate of the histologically diagnosed PC. Forty-eight lymph node and 29 bone metastases were detected in 16 and 9 patients, respectively. In addition, 3 patients had disseminated bone metastases. No distant organ metastases were found. Interobserver agreement was high for the overall scan result (97%), as well as for the detection of the primary tumor (97%), of lymph node metastases (97%), and of bone metastases (99%). Recurrence of PC occurred in 5 patients in whom follow-up was available (10%). TU prostate was significantly higher in patients with Gleason scores of 8 or greater compared with patients with Gleason scores of 7 or less and at prostate-specific antigen (PSA) serum levels of 10 ng/mL or greater compared with PSA serum levels of 10 ng/mL or less. TU prostate of greater than 26 in the primary tumor predicted the occurrence of lymph node or bone metastases with a sensitivity of 82% and specificity of 76%. Conclusions MIP-1404 SPECT/CT has a high accuracy and low interobserver variability in the diagnosis of PC and allows detection of lymph node and bone metastases in a significant proportion of as yet untreated PC patients. TU prostate is correlated with Gleason score and PSA serum concentration and allows prediction of the occurrence of lymph node and bone metastases with moderate accuracy at primary staging.
    Type of Medium: Online Resource
    ISSN: 1536-0229 , 0363-9762
    URL: Article
    DOI: 10.1097/RLU.0000000000001991
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    detail.hit.zdb_id: 2045053-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 10
    Online Resource
    Online Resource
    Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT : A Pilot Study in Patients With Metastatic Prostate Cancer
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  Clinical Nuclear Medicine Vol. 43, No. 8 ( 2018-8), p. e250-e258
    Details
    In: Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 43, No. 8 ( 2018-8), p. e250-e258
    Abstract: We investigated the role of 99m Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) SPECT/CT of PSMA expression in the assessment of treatment response in patients with metastatic prostate cancer. Methods We retrospectively analyzed 99m Tc-MIP-1404 SPECT/CT scans from 28 patients with metastatic prostate cancer examined before initiation and after completion of therapy. Eight of these patients had been treated with androgen deprivation therapy, 10 with docetaxel, and another 10 with external beam radiotherapy. On the CT images from SPECT/CT, treatment response was assessed according to RECIST 1.1 criteria; independently from that analysis, maximal standardized uptake values (SUV max ) were quantified in representative tumor lesions and treatment response assumed at differences in SUV max greater than 30%. Radiographic response assessment was correlated to biochemical response (BR) based on prostate-specific antigen serum levels. Results The concordance rate between SPECT and BR was 75% (95% confidence interval [CI], 0.55–0.89) (Cohen κ = 0.57; 95% CI, 0.29–0.85; P ≤ 0.01), higher than for that between SPECT and CT with 57% (95% CI, 0.37–0.76) (κ = 0.40; 95% CI, 0.14–0.65; P ≤ 0.01), as well as that between CT and BR with 50% (95% CI, 0.31–0.69) (κ = 0.31; 95% CI, 0.06–0.57, P ≤ 0.05). Discordant findings between SPECT and CT were most likely due to limitations of CT in assessing metastases in lymph nodes, as well as bone involvement, which was sometimes not detectable on CT scans. Conclusions The high agreement between treatment response, as assessed by 99m Tc-MIP-1404 SPECT/CT and BR, suggests a possible role of that imaging tool for monitoring treatment in metastatic prostate cancer. Larger, ideally prospective trials are needed to help to reveal the full potential of SPECT imaging of PSMA expression in that regard.
    Type of Medium: Online Resource
    ISSN: 1536-0229 , 0363-9762
    URL: Article
    DOI: 10.1097/RLU.0000000000002162
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    detail.hit.zdb_id: 2045053-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages